Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (495)	5/1/2001 7:05:07 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1169

<<Tuesday May 1, 12:00 pm Eastern Time RESEARCH ALERT-UBS cuts Aurora Biosciences NEW YORK, May 1 (Reuters) - UBS Warburg analyst Jeannie Lorenz said on Tuesday she had lowered her rating to a hold from a buy on biotechnology firm Aurora Biosciences Corp. (NasdaqNM:ABSC - news), and set a price target of $24. ``We are lowering our rating on ABSC... due to valuation,'' she said in a statement. On Monday, Vertex Pharmaceuticals Inc. (NasdaqNM:VRTX - news) had agreed to buy Aurora for about $592 million, or $24 per share, in a stock-for-stock deal. In early trade, Aurora was up 25 cents to $23.45 per share.>> Very brave? In other words, she is short VRTX. It remind me on MLNM, after they bought LKST. Will see how will this acquisition pain out, 12-16 months from now. Miljenko